A Five-year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis Formerly Treated in Study M02-497 (ReAct) and Subsequently Prescribed Humira.
Phase of Trial: Phase IV
Latest Information Update: 01 Jan 2014
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ReAct; ReAlise
- Sponsors Abbott Laboratories
- 31 Aug 2018 Biomarkers information updated
- 25 Aug 2011 Primary endpoints added as reported by ClinicalTrials.gov.
- 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.